A Phase Ia Clinical Trial Aimed at Evaluating the Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic (PK/PD) Characteristics of Single Dose of Telpegfilgrastim Injection in Healthy Premenopausal Non-pregnant Women
Latest Information Update: 11 Apr 2025
At a glance
- Drugs Telpegfilgrastim (Primary)
- Indications Preeclampsia
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Xiamen Amoytop Biotech
- 08 Apr 2025 Status changed from not yet recruiting to recruiting.
- 01 Apr 2025 New trial record